Tickers

1. Composite Trajectory Verdict

For a regulated electric utility, all three statements carry roughly equal weight because earnings reflect allowed returns on rate base, operating cash flow funds capital expenditures and dividends, and the balance sheet shows regulatory assets, leverage, and capital structure that influence future rate cases.

Composite Trajectory: Mixed

The income statement shows revenue and operating income growth but a decline in net income and EPS in 2025 due to higher interest expense and investment losses. Cash flow from operations has increased each year, supporting rising capital expenditures, though free cash flow remains negative. The balance sheet shows growing assets and equity but also rising long-term debt and commercial paper, with regulatory assets and liabilities expanding. These mixed signals result in a Mixed composite trajectory.

2. Red Flags

• Net income attributable to Evergy, Inc. decreased 2.0% to $855.6M in 2025 from $873.5M in 2024 despite a 4.4% increase in operating income, driven by a 9.4% rise in interest expense to $616.3M and a swing to other expense of -$25.6M from $3.1M due to $48.7M in losses on early-stage clean energy investments (10-K 2025, MD&A Earnings Overview; 10-K 2025, MD&A Evergy Results of Operations).
• Interest expense grew faster than operating income in 2025 (interest expense +$53.2M vs operating income +$64.9M), compressing pre-tax income (10-K 2025, MD&A Evergy Results of Operations).
• Commercial paper outstanding increased 15.4% to $1.394B at year-end 2025 from $1.208B at year-end 2024, indicating increased reliance on short-term funding (10-K 2025, Consolidated Balance Sheets).
• Long-term debt, net increased 10.4% to $13.039B in 2025 from $11.809B in 2024, while common equity ratio declined to 43% from 44% (10-K 2025, MD&A Capital Sources; 10-K 2025, Consolidated Balance Sheets).
• Regulatory assets (noncurrent) grew 9.7% to $1.885B and regulatory liabilities (noncurrent) grew 5.7% to $2.825B, reflecting increasing deferred costs and obligations pending regulatory recovery (10-K 2025, Consolidated Balance Sheets).
• Free cash flow (operating cash flow less capital expenditures) remained negative and widened to -$525M in 2025 from -$353M in 2024, as capex outpaced operating cash flow growth (10-K 2025, MD&A Cash Flows; 10-K 2025, MD&A Capital Expenditures).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Overall Assessment: Operating revenues grew 2.0% to $5.962B in 2025 from $5.847B in 2024, continuing a three-year upward trend (10-K 2025, MD&A Evergy Results of Operations). Operating income rose 4.4% to $1.533B from $1.468B (same). However, net income attributable to Evergy, Inc. fell 2.0% to $855.6M from $873.5M, and diluted EPS declined to $3.66 from $3.79, primarily due to a $53.2M increase in interest expense to $616.3M and a $28.7M swing in other income/expense to a net expense of $25.6M, largely from $48.7M in losses on non-regulated early-stage clean energy investments (10-K 2025, MD&A Earnings Overview; 10-K 2025, MD&A Other Income (Expense), Net). Adjusted earnings (non-GAAP) increased to $893.8M ($3.83/share) from $877.9M ($3.81/share), but the GAAP decline indicates earnings pressure from financing costs and investment volatility.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Improving

Overall Assessment: Cash flows from operating activities increased for the third consecutive year, reaching $2.045B in 2025, up 3.1% from $1.984B in 2024 and 3.3% from $1.980B in 2023 (10-K 2025, MD&A Cash Flows from Operating Activities). This growth supported a significant rise in capital expenditures to $2.797B in 2025 from $2.337B in 2024 (10-K 2025, MD&A Capital Expenditures). Cash flows from financing activities more than doubled to $522.0M in 2025 from $280.3M in 2024, driven by $1.688B of long-term debt issuances versus $1.414B in 2024 (10-K 2025, MD&A Cash Flows from Financing Activities). Despite higher investing outflows, operating cash flow growth and access to debt markets have maintained liquidity, with $1.1B of available borrowing capacity under the master credit facility at year-end 2025 (10-K 2025, MD&A Short-Term Borrowings).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Overall Assessment: Total assets grew 5.2% to $33.95B at December 31, 2025 from $32.28B a year earlier, driven by a 5.5% increase in net property, plant and equipment to $26.30B and a 9.7% rise in noncurrent regulatory assets to $1.885B (10-K 2025, Consolidated Balance Sheets). Total equity increased 2.8% to $10.27B, but the common equity ratio slipped to 43% from 44% as long-term debt (including VIEs) rose to 57% of capitalization from 56% (10-K 2025, MD&A Capital Sources). Long-term debt, net increased 10.4% to $13.04B, and commercial paper rose 15.4% to $1.394B, while current maturities of long-term debt fell 43.7% to $367M due to repayments and reclassifications (10-K 2025, Consolidated Balance Sheets; 10-K 2025, MD&A Significant Balance Sheet Changes). Noncurrent regulatory liabilities grew 5.7% to $2.825B, and the pension liability decreased 24.9% to $278.7M. The balance sheet reflects ongoing capital investment funded by debt, with regulatory assets and liabilities expanding in tandem.

6. Data Gaps

• Quarterly GAAP income statement, cash flow, and balance sheet data for 2026 quarters (Q1, Q2) and comparable 2025 quarters are not provided in the filing text; only annual 2023-2025 data is available from the 10-K.
• Free cash flow (operating cash flow minus capital expenditures) is not explicitly reported; it is derived here from operating cash flow and capex figures in the MD&A.
• The 10-Q filings for 2026-06-30, 2026-03-31, 2025-09-30, and 2025-06-30 are listed but their financial statement details are not included in the provided documents, preventing quarterly trend analysis.
• Detailed breakdown of "Other revenues" increase of $114.9M in 2025 is not fully explained in the provided text.
• The impact of the nuclear production tax credit (PTC) on cash flows and earnings is noted as uncertain pending IRS guidance (10-K 2025, MD&A Nuclear Production Tax Credit).